Eli Lilly launches citrate-free Taltz formulation
The latest move comes after the receipt of the US Food and Drug Administration (FDA) approval in May this year for the new formulation, which includes the same
The US Food and Drug Administration (FDA) has approved Genentech’s supplemental new drug application (sNDA) for xofluza (baloxavir marboxil) to treat influenza in children.
Under the collaboration, the company will partner with the MD Anderson scientists on preclinical trials for further validating TransCode’s RNA-targeted oncology therapy and diagnostic candidates. They will also
The investigational human monoclonal antibody, OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the main activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D
Healthcare venture capital firm Lapam Capital, investment management firm Junson Capital and Dyee Capital have led the financing round. BridGene’s IMTAC platform combines ‘cutting-edge’ technologies including chemical proteomics,